Crossmark Global Holdings Inc. Purchases 4,282 Shares of Amgen Inc. (NASDAQ:AMGN)

Crossmark Global Holdings Inc. raised its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,889 shares of the medical research company's stock after purchasing an additional 4,282 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Amgen were worth $25,201,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Pinney & Scofield Inc. bought a new position in Amgen in the 4th quarter valued at $26,000. First Pacific Financial grew its stake in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares during the period. Ritter Daniher Financial Advisory LLC DE grew its stake in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares during the period. Atala Financial Inc bought a new position in Amgen in the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen in the 4th quarter valued at $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Piper Sandler reissued an "overweight" rating and set a $328.00 price objective on shares of Amgen in a report on Friday, June 27th. Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Mizuho increased their price objective on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Finally, Royal Bank Of Canada reduced their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $307.82.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.69% of the company's stock.

Amgen Price Performance

Shares of AMGN stock traded down $5.29 on Monday, reaching $292.95. The company's stock had a trading volume of 2,143,871 shares, compared to its average volume of 2,846,304. The company has a market capitalization of $157.52 billion, a P/E ratio of 26.73, a PEG ratio of 2.70 and a beta of 0.49. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The stock's 50 day simple moving average is $282.47 and its 200-day simple moving average is $287.17. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $3.96 earnings per share. As a group, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.